Monday, Sep 21, 2020 | Last Update : 10:12 AM IST

180th Day Of Lockdown

Maharashtra118801585793332216 Andhra Pradesh6177765307115302 Tamil Nadu5364774812738751 Karnataka5113454048417922 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Telangana1713061397001033 Odisha167161133466722 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
  Life   Health  22 Oct 2019  Human bodies get resistant to antibiotics for treating harmful bacteria

Human bodies get resistant to antibiotics for treating harmful bacteria

Published : Oct 22, 2019, 9:43 am IST
Updated : Oct 22, 2019, 9:43 am IST

Studies reveal that human body resists antibiotics for treating harmful bacteria for multiple stomach conditions.

The research was presented today at UEG Week Barcelona 2019. (Photo: ANI)
 The research was presented today at UEG Week Barcelona 2019. (Photo: ANI)

Washington: A recent study has discovered that the human body starts getting resistant to antibiotics for treating harmful bacteria for a variety of stomach conditions, and the changes have more than doubled in 20 years.

Antibiotic resistance occurs when bacteria develop the ability to survive exposure to medications designed to kill or halt their growth. It is one of the greatest threats to global health today, causing more than 750,000 deaths every year and, without urgent action, this number is expected to rise dramatically in the future.


The research was presented today at UEG Week Barcelona 2019. The study analysed 1,232 patients from 18 countries across Europe, investigated resistance to antibiotics regularly taken for 'helicobacter pylori' (H. pylori) infection, a harmful bacterium associated with gastric ulcer, lymphoma, and gastric cancer.

Presenting the study, lead researcher Prof Francis Megraud explained: " 'H pylori infection is already a complex condition to treat, requiring a combination of medications. With resistance rates to commonly used antibiotics such as clarithromycin increasing at an alarming rate of nearly one per cent per year, treatment options for 'H pylori' will become progressively limited and ineffective if novel treatment strategies remain undeveloped."


'H pylori' is one of the most common bacterial infections in humans and is estimated to be present in one-half of the world's population. 'H pylori' leads to inflammation of the stomach lining, namely gastritis, which can result in peptic ulcers.

Underlining the severity of the situation, in 2017, the World Health Organisation (WHO) identified clarithromycin-resistant 'H pylori' as a high priority bacterium for antibiotic research and development.

The survey also found that the rates of primary clarithromycin resistance in 'H pylori' were highest in southern Italy (39.9 per cent), Croatia (34.6 per cent) and Greece (30 per cent), aligning with previous reports that predict that both Italy and Greece will have the highest number of deaths due to antimicrobial resistance amongst EU members by 20507.


The high levels of resistance exhibited in these countries have been attributed to the overconsumption of antibiotics for conditions including cold and flu, and a lack of institutional support for antibiotic resistance containment strategies.

"The findings of this study are certainly concerning, as 'H pylori' is the main cause of peptic disease and gastric cancer," commented Mario Dinis-Ribeiro, president of the European Society of Gastrointestinal Endoscopy. "The increasing resistance of 'H pylori' to a number of commonly-used antibiotics may jeopardise prevention strategies."

Tags: antibiotics, bacteria, gastric cancer